晚期慢性肾病患者植入型心律转复除颤器与再同步治疗:JACC前沿综述
心力衰竭与慢性肾病常共存,晚期心衰的电生理改变可致传导异常、收缩不同步及室性心律失常,进而引发心脏骤停。该综述探讨合并晚期慢性肾病对ICD与CRT疗效和安全性的影响、现有证据及未来方向。
要点
- 晚期慢性肾病可改变心衰患者ICD与CRT的疗效与安全性。
- 心衰电生理改变致传导异常、不同步收缩及室性心律失常。
- 合并晚期肾病时器械管理更复杂,需个体化评估。
核心结论
- 合并晚期慢性肾病时,相关病理生理心血管改变可影响ICD与CRT的疗效和安全性并使管理复杂化。
研究设计与样本
- JACC前沿综述,探讨合并晚期心衰与晚期慢性肾病对ICD和CRT疗效与安全性的影响及现有证据。
主要发现
- 晚期心衰的电生理改变常导致传导异常、收缩不同步及室性心律失常,可引发心脏骤停。
- 合并晚期慢性肾病时,相关病理生理心血管改变可改变这些干预的疗效与安全性。
临床怎么用
- 对合并晚期慢性肾病的心衰患者评估ICD或CRT时,需考虑肾病相关病理生理改变对疗效与安全性的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Heart failure and chronic kidney disease are common and clinically important conditions that regularly coexist. Electrophysiologic changes of advanced heart failure often result in abnormal conduction, causing dyssynchronous contraction, and development of ventricular arrhythmias, which can lead to sudden cardiac arrest. In the last 2 decades, implantable cardioverter-defibrillator and cardiac resynchronization therapy devices have been developed to address these complications. However, when the coexisting chronic kidney disease is advanced, the associated pathophysiologic cardiovascular changes can alter the efficacy and safety of those interventions and complicate the management. This review explores the impact of comorbid advanced heart failure and advanced chronic kidney disease on the efficacy and safety of implantable cardioverter-defibrillator and cardiac resynchronization therapy, the currently available evidence, and potential future directions.
引用
- Varga CR, Cleland JGF, Abraham WT, et al. Implantable Cardioverter Defibrillator and Resynchronization Therapy in Patients With Overt Chronic Kidney Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2024. PMID: 39322329. doi:10.1016/j.jacc.2024.05.081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。